ALPN - Alpine Immune Sciences, Inc.
| Previous Close | 7.76 |
| Open | 7.75 |
| Bid | 7.53 x 900 |
| Ask | 7.67 x 800 |
| Day's Range | 7.54 - 7.75 |
| 52 Week Range | 6.85 - 12.87 |
| Volume | 2,759 |
| Avg. Volume | 20,128 |
| Market Cap | 104.426M |
| Beta | 0.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.13 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.00 |
- Business Wire•last month
Alpine Immune Sciences to Present at Jefferies 2018 Global Healthcare Conference
Alpine Immune Sciences, Inc. , a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, today announced the company will present at the Jefferies 2018 Global Healthcare Conference on Tuesday, June 5 2018 at 4:30 pm Eastern Time in New York, NY.
- Benzinga•last month
Alpine Is A Buy Ahead Of Clinical Trials, Wedbush Says In Positive Initiation
Wedbush analysts see an attractive entry point for Alpine Immune Sciences Inc. (NASDAQ: ALPN ), as the biotech 's initial candidates will enter the clinic over the next year. The Analyst Robert Driscoll ...
- Business Wire•last month
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2018 Financial Results
Alpine Immune Sciences, Inc. , a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, provided a corporate update and reported financial results for the first quarter ended March 31, 2018.
- Business Wire•2 months ago
Alpine Immune Sciences Appoints Life Sciences Executive Chris Peetz to its Board of Directors
Alpine Immune Sciences, Inc. announced today the appointment of Chris Peetz to its Board of Directors. Mr. Peetz, an experienced life sciences executive, currently serves as the Chief Executive Officer of Flashlight Therapeutics.
- Business Wire•2 months ago
Alpine Immune Sciences Announces Preclinical Data Demonstrating ALPN-202 Eliminates Tumors and Creates Persistent Tumor Resistance in a Murine Cancer Model
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing treatments for cancer and autoimmune/inflammatory diseases, today presented preclinical study results of its ALPN-202 immuno-oncology program.
- ACCESSWIRE•2 months ago
Blog Exposure - ImmunoCellular Therapeutics Reported Achievement of Next Key Milestone in Validating Stem-to-T-Cell Program
Stock Monitor: Alpine Immune Sciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 16, 2018 / Active-Investors.com has just released a free research report on ImmunoCellular Therapeutics, Ltd ...
- Business Wire•3 months ago
Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2017 Financial Results
Alpine Immune Sciences, Inc. , a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune, and inflammatory diseases, today provided a corporate update and reported financial results for the year ended December 31, 2017.
- Business Wire•3 months ago
Alpine Immune Sciences Announces Poster Presentation at the 2018 AACR Annual Meeting
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the 2018 American Association for Cancer Research Annual Meeting taking place April 14 - 18, 2018 in Chicago, Illinois.
- Business Wire•4 months ago
Alpine Immune Sciences to Present at Cowen 38th Annual Health Care Conference
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced the company will present at the Cowen 38th Annual Health Care Conference in Boston on Monday, March 12, 2018 at 4:10 pm Eastern Time.
- Business Wire•7 months ago
Alpine Immune Sciences Announces Preclinical Data from ALPN-101 Program Demonstrating Efficacy in Humanized Model of Graft Versus Host Disease
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced results from a preclinical study of the company’s ALPN-101 program in a humanized model of graft vs.
- Business Wire•7 months ago
Alpine Immune Sciences Announces Preclinical Data Showing Novel Immuno-Oncology Costimulatory Molecules Generated from vIgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor Cells
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced results of a preclinical study of novel immuno-oncology molecules derived from the company’s variant immunoglobulin domain platform.
- Business Wire•7 months ago
Alpine Immune Sciences Reports Corporate Update and Third Quarter 2017 Financial Results
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today provided a corporate update and reported financial results for the third quarter ended September 30, 2017.
- Business Wire•7 months ago
Alpine Immune Sciences Presents Preclinical Data on Novel Immuno-Oncology Molecules at the Society for Immunotherapy of Cancer’s 32nd Annual Meeting
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced immuno-oncology preclinical data characterizing the functional activity of molecules Alpine successfully generated from its variant immunoglobulin domain platform.
- Business Wire•8 months ago
Alpine Immune Sciences Presents ALPN-101 Program Data Demonstrating Potent Preclinical Activity in Arthritis and Inflammation
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing treatments for autoimmune diseases and cancer, today announced results from preclinical studies evaluating ALPN-101 program dual ICOS/CD28 antagonists generated by the company’s variant immunoglobulin domain platform.
- Business Wire•8 months ago
Alpine Immune Sciences and Kite Extend Research Term of Collaboration to Create Next-Generation CAR-T and TCRs
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing treatments for autoimmune diseases and cancer, today announced it has extended the research term of its worldwide research and license agreement with Kite, a Gilead company.
- Business Wire•8 months ago
Alpine Immune Sciences Announces Upcoming Scientific Presentations
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced planne
- Business Wire•9 months ago
Alpine Immune Sciences Announces Poster Presentation at 2017 ACR/ARHP Annual Meeting
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced a planned poster presentation highlighting recent data from a preclinical study evaluating dual ICOS/CD28 antagonists generated by the Company’s vlgD™ platform at the upcoming 2017 American College of Rheumatology Annual Meeting being held ...
- Business Wire•9 months ago
Alpine Immune Sciences to Present at Ladenburg Thalmann 2017 Healthcare Conference
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on the development of treatments for autoimmune/inflammatory diseases and cancer, announced today that the company will present at the Ladenburg Thalmann 2017 Healthcare Conference in New York on Tuesday, September 26, 2017, at 10:00am Eastern Time.
Zacks•11 months agoStrength Seen in FibroGen (FGEN): Stock Soars 48.2%
FibroGen (FGEN) was a big mover last session, as the company saw its shares rise over 48% on the day amid huge volumes.
Zacks•11 months agoCorcept (CORT) Looks Good: Stock Moves Up 8.8% in Session
Corcept Therapeutics Incorporated (CORT) moved big last session, as its shares rose over 8% on the day.
- Business Wire•11 months ago
Alpine Immune Sciences, Inc. Completes Merger with Nivalis Therapeutics, Inc.
Alpine Immune Sciences, Inc. , a leading company focused on the development of proprietary, protein-based immunotherapies to modulate the immune system, today announced the closing of its previously disclosed merger with Nivalis Therapeutics , effective July 24, 2017.